scholarly journals Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: All that is gold does not glitter, not all those who wander are lost

Hepatology ◽  
2015 ◽  
Vol 61 (6) ◽  
pp. 2104-2106 ◽  
Author(s):  
Giovanni Musso
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Obeticholic Acid ◽  
Nonalcoholic Fatty Liver

scholarly journals Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease

2018 ◽  
Vol 11 (4) ◽  
pp. 104 ◽  
Author(s):  
Ludovico Abenavoli ◽  
Tetyana Falalyeyeva ◽  
Luigi Boccuto ◽  
Olena Tsyryuk ◽  
Nazarii Kobyliak
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Hepatic Metabolism ◽  
Lifestyle Changes ◽  
Farnesoid X Receptor ◽  
Primary Biliary Cholangitis ◽  
Obeticholic Acid ◽  
Nonalcoholic Fatty Liver

The main treatments for patients with nonalcoholic fatty liver disease (NAFLD) are currently based on lifestyle changes, including ponderal decrease and dietary management. However, a subgroup of patients with nonalcoholic steatohepatitis (NASH), who are unable to modify their lifestyle successfully, may benefit from pharmaceutical support. Several drugs targeting pathogenic mechanisms of NAFLD have been evaluated in clinical trials for the treatment of NASH. Farnesoid X receptor (FXR) is a nuclear key regulator controlling several processes of the hepatic metabolism. NAFLD has been proven to be associated with abnormal FXR activity. Obeticholic acid (OCA) is a first-in-class selective FXR agonist with anticholestatic and hepato-protective properties. Currently, OCA is registered for the treatment of primary biliary cholangitis. However, promising effects of OCA on NASH and its metabolic features have been reported in several studies.

Sign in / Sign up

Export Citation Format

Share Document